Documente Academic
Documente Profesional
Documente Cultură
MATRIX
LifeCell's Transplant Matrix enlists the
stem cell transplants performed using
the preserved umbilical cord samples
retrieved from LifeCell's laboratory. This
white paper elucidates a detailed
analysis of the samples retrieved through
statistical evidence including age range
of the patients, transplant type, sample
criteria and much more. This collective
information will help us understand how
cord blood banking contributes to
therapeutic care through stem cell
transplants.
Transplant Matrix
Gender distribution
Male Female
26 Samples 19 Samples
Type of Transplants
Autologous: Uses patient’s own stem cells Allogenic: Uses donor stem cells
Autologous Allogenic
7 cases 38 cases
[ 6 - Spastic Cerebral Palsy
1 - Autism Spectrum Disorder [
06 Years 11 Years
25th & 45th Case 31st Case
Human Leukocyte Antigens are proteins on the surface of our cells that helps the immune
system to identify the cells that belong to our body. The best transplant outcome happens when
a patient's HLA and the donor's HLA closely match.
HLA typing is used to match the compatibility of the patient with a donor for stem cell transplant
A 4 out of 6 HLA match (~67% match) between the patient and the donor is sufficient for umbilical
cord blood stem cell transplant while other stem cell sources may require 100% full match.
Reference: http://www.nationalcordbloodprogram.org/public_hla_search.html
For disaster management, sample back-up and added retention security, LifeCell offers an
exclusive two-site storage service which helps in the preservation of stem cell samples in
LifeCell's Chennai and Gurgaon facilities.
SINGLE DUAL
STORAGE 35 10 STORAGE
Gurgaon
Chennai Chennai
Of the 45 retrieved samples, 35 samples were preserved in LifeCell's Chennai laboratory alone
(Single Site Storage) and 10 samples were preserved at two sites - LifeCell's Chennai and
Gurgaon (Manesar) laboratories (Dual Site Storage).
Transplant Matrix
35
30 05 ml : 01 case
Number Of Retrivals
25
20
09 ml : 06 cases
15
20 ml : 01 case
10
05
25 ml : 37 cases
05 10 15 20 25 30
Sample Volume
* At LifeCell, between 2004 to 2006, the processed cord blood units were stored in two cryo-vials of 4.5 mL each (total 9mL). With
continuous improvements in the CBU storage technology, from 2007 onwards, the processed cord blood units are being stored in
US FDA compliant special cryo-bags which are compartmentalized into 20 mL main bag and 5 mL pilot bag. This distribution
means greater flexibility for future sample access.
Transplant Matrix
07
36
01
01
TOTAL
Medical Condition / Diagnosis
Transplant Outcomes
Reference: http://parentsguidecordblood.org/en/news/cord-blood-transplants-
95% thalassaemia-india
Reference: Excerpts from 'Cellular Horizon' International conference held at Vatican City from 28 – 30 April 2016 [unpublished
data]
Transplant Matrix
Brig (Dr.) Paramjit Dhot, VSM Established in 2004, LifeCell is India's first and largest
Medical Director stem cell bank, enjoying the trust of over 2 lakh parents
who have banked their children's stem cells with the
Dr. Chirayu Padhiar company. With state-of-the-art facilities and a spread
Laboratory Director over 200 centers in the country and footprints in GCC
countries, LifeCell is also the most recommended stem
Dr. SM. Salahudeen cell bank by gynaecologists. The company has
Vice President I Cellular Therapy accreditations from international organizations for
standards such as American Association of Blood
Mr. Vinesh Mandot Banks (AABB), College of American Pathologists (CAP),
Senior Manager - Sales Excellence WHO GMP and National Accreditation Board for Testing
& Calibration Laboratories (NABL), US FDA registration
among others. LifeCell is also the only player in the
industry providing comprehensive stem cell solutions
including menstrual stem cell banking, R&D and point-
of-care stem cell therapy for orthopaedic, vascular
specialties.
Disclaimer:
Banking cord blood does not guarantee treatment outcomes. The use of umbilical cord stem cells to treat a medical condition is the
decision of treating transplant physician based on the suitability of the treatment and whether the source of stem cells is autologous
(self) or allogenic (suitable donor- siblings of the same biological parents have a 25% chance of a perfect match and a 50% chance of a
partial match; biological parents have partial match). Currently, umbilical cord tissue stem cells are not approved for clinical use since
they are evaluated under clinical trials and hence its use depends on the ongoing research. There is no guarantee that treatments
studied in the laboratory, clinical trials and other experimental treatments (including regenerative medicine applications) shall be
available in the future.